Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stig P. Cramer
Permeability of the Blood-Brain Barrier Predicts No Evidence of Disease Activity at Two Years After Natalizumab or Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis
Annals of Neurology
Neurology
Relationship Between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
PLoS ONE
Multidisciplinary
Related publications
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
Neurotherapeutics
Neurology
Pharmacology
Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod
Therapeutic Advances in Neurological Disorders
Neurology
Pharmacology
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
Advances in Therapy
Medicine
Pharmacology
IL-17A Is Associated With the Breakdown of the Blood-Brain Barrier in Relapsing-Remitting Multiple Sclerosis
Journal of Neuroimmunology
Allergy
Immunology
Neurology
Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics
Health Policy
Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis
Advances in Clinical and Experimental Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
Multiple Sclerosis International
Neurology
